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Introduction
In recent years there has been a dramatic increase in the importance given to the theory that the tissue microenvironment participates in determining the bone niche in the progression of bone tumours and in establishing resistance processes to conventional therapies Originally the concept of tumour niche has emerged based on the seed and soil theory proposed by Stephan Paget at the end of the nineteenth century , ]. This tumour niche is de ned as a speci c microenvironment promoting the emergence of cancer initiating cells and providing all the factors required for their quiescence proliferation and migration Therefore the tumour microenvironment is composed of a complex interconnected network of protagonists including soluble factors such as cytokines extracellular matrix components interacting with broblasts endothelial cells immune cells and various speci c cell types depending on the location of the cancer cells e g osteoblasts osteoclasts in the bone tissue or pulmonary epithelium in case of lung metastasis This cellular diversity de nes three main niches depending on their functional implication an immune niche involved in local immune tolerance a vascular niche associated with tumour cell extravasation migration and a metastatic niche e g bone lung and liver hosting the metastatic tumour cells 3, 4].
The concept of bone niche was initially described in the context of haematological malignancies such as leukaemia 5 or multiple myeloma 6 and then extended to bone metastases such as breast or prostate cancers 7 As all tumours the pathogenesis of osteosarcoma OS is closely related to the microenvironment in which the tumour grows Even though the aetiology of OS has not been clearly established its development has the special feature of being strongly associated with the soil described by Paget In physiological and pathological bone tissue the various cells communicate together by direct contacts involving adhesion molecules or channels but also in an autocrine paracrine endocrine manner involving cytokines and growth factors 8 Among these glycoproteins the triad osteoprotegerin OPG Receptor Activator of NF B RANK RANK Ligand RANKL plays a pivotal role in OS development 9 In case of OS there is e ectively a dysregulation in this balance between OPG RANK RANKL provoking exacerbated local bone remodelling Figure 1 As a result numerous factors initially trapped in this matrix are released which in turn stimulate sarcoma cell proliferation leading to the establishment of a vicious cycle between bone and tumour cells These events are associated with early and late events in the metastatic process by promoting the neoangiogenesis and extravasation of tumour cells , But until today the characterisation of the microenvironment of OS has not been fully documented , ]. The immune niche with its huge cell diversity including more speci cally tumour in ltrating lymphocytes TILs and tumour associated macrophages TAMs regulates the OS microenvironment , TAMs exert di erent e ects on tumour development because of their polarisation In oncology M polarised macrophages are considered to be anti tumour e ectors and M polarised macrophages are de ned as pro tumour modulators as they increase the neoangiogenic process -The density of TAMs is correlated with tumour cell proliferation invasion metastasis and poor prognosis in various epithelial and haematological cancers and in bone metastases ].
Osteoimmunology is a recent term proposed for describing the complex immune environment controlling the bone remodelling and related diseases Several reports have underlined the therapeutic interest to use immunotherapies or immunomodulatory based therapies for OS In this context the number of new drugs activating the immune system has exploded in the last years and numerous phase I and II clinical trials are in progress in OS The present chapter will describe the main roles of the immune system in the pathogenesis of OS and the most recent therapeutic development based on its regulation
The immune niche in osteosarcoma
As said above the niche of OS is composed of a complex network of diverse cells which interact together by direct contacts or in an autocrine paracrine endocrine manner involving cytokines and growth factors This chapter will focus speci cally on the main cellular protagonists lymphocytes macrophages and the principal associated cytokines
Tumour in ltrating lymphocytes TILs
Heterogeneity of tumour cells with various osteosarcoma sub entities further complicates identi cation of robust biomarkers with broad clinical application Analysis of the tumour microenvironment in patients with a variety of haematological pathologies and solid tumours such as bone metastases and soft tissue sarcomas has revealed that a major subset of tumours shows evidence of a T cell in ltrated phenotype , Selected T lymphocytes migrate from secondary lymphoid organs to the tumour sites and invade the tumour tissues They are composed of various T lymphocyte subpopulations which exhibit highly speci c immunological Figure 1 . Osteosarcoma and its niches In osteosarcoma the microenvironment plays a pivotal role in the pathogenesis of tumour cells It facilitates the transport of gas and nutriments to cancer cells and extravasation to their metastatic location vascular niche induces a tolerant environment immune niche and dysregulates bone remodelling bone niche in which the molecular OPG RANKL RANK triad plays a key role in regulation OPG and RANKL are produced by osteoblasts and or stromal cells whereas RANK is expressed at the surface of osteoclasts and their precursors The immune niche is one of the source of therapeutic targets against osteosarcoma reactivity compared to circulating and non in ltrating lymphocytes
The nal immune response resulting from the activation of T lymphocytes is complex and depends on the nature of these T cells e g Treg CD Treg was unknown and not included in the study which did not detect any correlation of TILs with OS outcome A few years later Theoleyre et al supported the presence of speci c T subpopulations in OS TILs isolated from OS samples exhibited lytic activity in vitro which were apparently no e cient in patients
The study of the microenvironment has a strong impact on targeted patient treatment for which li le progress has been achieved since introduction of neo adjuvant chemotherapy years ago Prognostic biomarkers for risk strati cation at the time of diagnosis are missing and are a major drawback in clinical testing of novel therapeutic agents Alternatively analysis of the tumour microenvironment for osteosarcoma outcome related biomarkers might be less dependent from the osteosarcoma subtype Recently Fri sching et al have reported for the rst time CD + FOXP + ratio as strong prognostic factor at time of OS diagnosis pointing out the functional key role of Treg in OS pathogenesis Multivariate analysis showed that this novel parameter was independent from tumour metastasis and response to neoadjuvant chemotherapy and could be validated in an independent patient cohort with current state of diagnosis and treatment of OS It has been suggested in other solid tumours e g colon cancers that intensity of tumour microenvironment in ltration with T cells especially cytotoxic tumour in ltrating CD + T cells CD + TILs allows more powerful prognostic staging than traditional staging The characterisation of this simple immune system based biomarker has been termed the immunoscore and this is currently tested for some tumours in a multicenter study , ].
Lymphocytes are immune cells regulated by diverse cytokines in particular the triad OPG RANK RANKL which represents a se ing up a fertile soil for cancer cells as well 9 Bone remodelling results from a balance between two opposite cellular activities i osteoblasts in charge of the synthesis of new organic extracellular matrix which will become progressively mineralized and ii osteoclasts specialised in the degradation of the mineralised extracellular matrix process named bone resorption Osteoclastogenesis and osteoclast activities are regulated by a master cytokine called NF B Ligand RANKL member of the tumour necrosis factor TNF superfamily o cial TNF nomenclature TNFSF 9 RANKL is a soluble and or membrane cytokine expressed by osteoblasts and stromal cells binds to RANK a membrane receptor expressed at the surface of mature osteoclasts and their precursors RANKL binding to RANK induces speci c NF B dependent signal transduction pathways and stimulates osteoclast di erentiation survival and resorption activity RANKL binds to a soluble receptor named osteoprotegerin OPG which is a ubiquitous protein and acts as a decoy blocking RANKL binding to RANK OPG is then considered as a strong inhibitor of osteoclastogenesis and bone resorption LGR is the last receptor of RANK recently identi ed LGR expressed at the osteoclast osteoclast precursor membrane is a negative regulator of RANKL RANK activation see review in Ref 9 It is widely accepted that the multiple components of the bone niche e g soluble factors extracellular matrix strongly contribute to the bone tumour initiation and the metastatic process , RANKL in uences the microenvironment of cancer cells by acting on the local immunity Indeed the major role of RANKL in the immune system has been initially identi ed in RANKL knockout mice in which the development of secondary lymphoid organs was impaired especially the lymph nodes but also at the central level where the maturation of thymic epithelial cells necessary for T cell development was a ected 33 RANKL is also involved in the modulation of the immune response by inducing T cell proliferation 34 and dendritic cells survival RANK is present at the cell membrane of monocytes macrophages and RANKL acts as chemoa ractant factor for these cells M subtype is strongly associated with the angiogenic process and interestingly RANK is mainly expressed by M macrophage subtype 53 RANK RANKL signalling in M subtype modulates the production of chemokines promoting the proliferation of Treg lymphocytes in favour of an immunosuppressive environment 54 In breast carcinoma RANKL is mainly produced by CD + CD + T lymphocytes expressing Foxp and corresponding to Treg lymphocytes In this context a vicious cycle is established between TAMs Treg and tumour cells resulting in the tumour growth the spreading of cancer cells and the ampli cation of the metastatic process 55].
Recent therapeutic developments based on the regulation of the immune system of osteosarcoma immunomodulating drugs
The therapeutic protocol currently used for osteosarcoma was established by Rosen et al at the end of the s 56 It comprises preoperative neoadjuvant chemotherapy associating mainly four drugs doxorubicin cisplatin methotrexate and ifosfamide 57 and followed by surgical removal of all detectable disease including metastases and postoperative adjuvant chemotherapy preferably within the se ing of clinical trials 58 OS is considered resistant to applicable doses of radiation 59, Supplemental therapeutic approaches such as chemoembolisation or angioembolisation thermal ablation radiofrequency ablation and cryotherapy are experimental or palliative 59 Unfortunately patients who are diagnosed with metastatic disease or who relapse post therapy have an extremely poor prognosis with li le to no improvements in survival seen over the past years Several reports have underlined the therapeutic value of using immunotherapies or immunomodulatory based therapies for osteosarcoma , -64 In this context the number of new drugs activating the immune system has exploded in the last years and numerous phase I and II clinical trials are in progress in osteosarcoma Figure 1 In this chapter the most recent therapeutic developments targeting the regulation of T lymphocytes and macrophages will be exposed
T-cell therapies
Detection of speci c T lymphocyte populations in the tumour microenvironment and in human tumour tissues de nes an immunoscore and leads to patient strati cation based on this immunophenotyping These analyses have identi ed new predictive biomarkers and new therapeutic targets which have stimulated the development of immunotherapies 65].
Disialoganglioside (GD2)
Monoclonal antibodies targeted against cell surface antigens speci c to tumour cells have been proven to be e ective in patients with breast cancer lymphoma and neuroblastoma 66-68 Usually these bispeci c antibodies are engineered antibodies linking a tumour antigen recognition domain to a second domain that activates a receptor on immune e ector cells typically T cells The expression of the glycosphingolipid GD is restricted to the central and peripheral nervous system skin melanocyte and mesenchymal cells located in the stroma
69-
In addition to the healthy tissues GD was detected in neuroblastomas melanomas sarcomas lung and central nervous system tumours in which a variable number of cancer cells express this antigen -75 Based on this relative restricted distribution GD targeting appeared very quickly as an interesting immunotherapy especially for high risk neuroblastomas for which anti GD antibodies improved signi cantly patient survival 68, 76 In patients with stage IV neuroblastoma anti GD antibody ch has been shown to improve EFS e ectively when given in the se ing of minimal residual disease The rationale for using this antibody in patients with OS lies in that of osteosarcoma express GD 77]. Consequently given the success of anti GD mAb therapy in neuroblastoma studies exploring the use of these mAbs in OS are underway 78 Current trials include the GD mAbs humanized F NCT and NCT and hu K A NCT ].
Nivolumab
Nivolumab is an immunomodulator which acts by blocking the activation of the programmed cell death PD receptor induced by one of its two ligands PD L on activated T cells 79 Numerous preclinical investigations have demonstrated that inhibition of the interaction between PD and PD L enhances the T cell response resulting in increased anti tumour activity PD L or PD blockade with monoclonal antibodies results in strong and often rapid anti tumour e ects in several mouse models A high PD L expression has been identi ed in OS cell lines and PD expression on CD and CD T cells was found higher in OS patients than in healthy controls and in patients with metastasis at diagnosis high tumour stage or bone fracture A phase I II trial will be conclude in on refractory solid tumours and sarcomas including osteosarcoma A total of patients will be enrolled and treated with Nivolumab IV over minutes twice a month Courses repeat every days in the absence of disease progression or unacceptable toxicity
Immune and dendritic cell vaccine
Dendritic cells have the speci c ability to initiate and modulate adaptive immune responses This speci city associated with their role in antigen presentation has led to their use in vaccine approaches in cancer Matured autologous dendritic cells loaded with tumour lysates derived from tumour tissue were used as the vaccine product In a pre clinical model of osteosarcoma it has been demonstrated that killer dendritic cells were able to induce an adaptive anti tumour immune response with a decrease in tumour development after cross presentation of the tumour cell derived antigen 83 A phase I clinical trial demonstrated the feasibility and good tolerance of dendritic cells pulsed with MAGE A MAGE A and NYESO full length peptides in combination with decitabine Anti tumour activity was observed in some patients
84
In osteosarcoma patients were vaccinated with tumour lysate pulsed dendritic cells but evidence of a clinical bene t was observed in only two of these patients 85]. These authors concluded that osteosarcoma patients may be relatively insensitive to DC based vaccine treatments A new clinical trial was initiated enrolling patients year with con rmed sarcoma either relapsed or without known curative therapies and treated with autologous dendritic cells pulsed with tumour lysate NCT is a pilot trial Pilot Study of Expanded Activated Haploidentical Natural Killer Cell Infusions for Sarcomas NKEXPSARC analysing the e ect of donor NK cells on clinical response determined by imaging About patients aged months years will be included between and The patients will receive lymphodepleting chemotherapy with cyclophosphamide day followed by udarabine days and each patient will receive IL day before infusion of the NK cell total six doses
Mifamurtide (liposomal-muramyl tripeptide phosphatidyl-ethanolamine L-MTP-PE)
As it has been discussed above the density of TAM is linked to a poor diagnosis In osteosarcoma Buddingh et al showed that macrophages exhibit M and M phenotypes and demonstrated a link between M macrophages and angiogenesis Similarly in preclinical models of osteosarcoma the recruitment of the M subtype is correlated with tumour angiogenesis and lung metastasis 47, ].
L MTP PE is a synthetic analogue of muramyl dipeptide of the bacterial cell walls which was identi ed as a powerful activator or monocyte macrophage lineage Indeed L MTP PE induces the expression of pro in ammatory mediators such TNF IL IL lymphocyte function associated antigen LFA and intercellular adhesion molecule ICAM leading to an M macrophage response The therapeutic interest of L MTP PE was widely studied in osteosarcoma 86, 87 The largest clinical experience with combination chemotherapy and L MTP derives from the Intergroup osteosarcoma study No di erence in survival was found for patients who received ifosfamide in addition to the standard three drug chemotherapy doxorubicin cisplatin and methotrexate But this study did suggest that L MTP had a bene cial impact on survival improving the year overall survival rate from to p 88 However no signi cant di erence in survival was observed 
Inhaled granulocyte-macrophage colony stimulating factor (GM-CSF)
GM CSF is one of the master regulators of myeloid cell lineage by controlling their di erentiation proliferation and activities Indeed this growth factor exerts immunomodulatory and immunostimulatory activities by stimulating the functional activities of neutrophil granulocytes but also of macrophages and DC More speci cally GM CSF promotes the recruitment and cytotoxic functions of macrophages stimulates natural killer and dendritic cells and consequently upmodulates the number of CD T lymphocytes Arndt et al have recently performed a phase I clinical trial using inhaled GM CSF in patients with rst isolated pulmonary recurrence of OS Unfortunately even though the clinical studies demonstrated the safety of administered GM CSF e g aerosolized delivery no biological bene t e g local immunomodulation in lung metastases or improved clinical outcome was demonstrated A future larger prospective randomised trial may demonstrate improved outcomes in OS patients probably , ].
Conclusion
The therapies focused on the immune niche partially represent the potential therapeutic targets available for OS nowadays Blood vessels bone cells and tumour cells are targeted as well in the current clinical trials However in the future the key to success will lie in be er understanding and characterisation of the disease leading to be er patient strati cation and consequently to personalised medicine 
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